Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes

We report that Imetelstat, a telomerase inhibitor that binds to the RNA component of telomerase (hTR), can sensitize primary CLL lymphocytes to fludarabine in vitro. This effect was observed in lymphocytes from clinically resistant cases and with cytogenetic abnormalities associated with bad prognosis. Imetelstat mediated-sensitization to fludarabine was not associated with telomerase activity, but with the basal expression of Ku80. Since both Imetelstat and Ku80 bind hTR, we assessed 1) if Ku80 and Imetelstat alter each other's binding to hTR in vitro and 2) the effect of an oligonucleotide complementary to the Ku binding site in hTR (Ku oligo) on the survival of primary CLL lymphocytes exposed to fludarabine. We show that Imetelstat interferes with the binding of Ku70/80 (Ku) to hTR and that the Ku oligo can sensitize CLL lymphocytes to FLU. Our results suggest that Ku binding to hTR may contribute to fludarabine resistance in CLL lmphocytes. This is the first report highlighting the potentially broad effectiveness of Imetelstat in CLL, and the potential biological and clinical implications of a functional interaction between Ku and hTR in primary human cancer cells.

[1]  M. Bergqvist,et al.  Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. , 2012, Biochimica et biophysica acta.

[2]  L. Bonaldi,et al.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes , 2012, Haematologica.

[3]  L. Panasci,et al.  ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro , 2011, Leukemia.

[4]  J. Shay,et al.  Processive and distributive extension of human telomeres by telomerase under homeostatic and nonequilibrium conditions. , 2011, Molecular cell.

[5]  R. Küppers,et al.  Telomeres and prognosis in patients with chronic lymphocytic leukaemia , 2011, International journal of hematology.

[6]  S. Heim,et al.  ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro , 2011 .

[7]  M. Egorin,et al.  A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients , 2011, Cancer Chemotherapy and Pharmacology.

[8]  M. Maitland,et al.  388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors , 2010 .

[9]  C. Harley,et al.  Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms , 2010, PloS one.

[10]  S. Lees-Miller,et al.  The human telomerase RNA component, hTR, activates the DNA-dependent protein kinase to phosphorylate heterogeneous nuclear ribonucleoprotein A1 , 2009, Nucleic acids research.

[11]  Yongbao Wang,et al.  Ku86 represses lethal telomere deletion events in human somatic cells , 2009, Proceedings of the National Academy of Sciences.

[12]  M. González-Cid,et al.  Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells. , 2008, Mutation research.

[13]  F. Bollmann.  The many faces of telomerase: emerging extratelomeric effects , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[14]  Emili Montserrat,et al.  New prognostic markers in chronic lymphocytic leukemia. , 2008, Blood reviews.

[15]  A. Pettitt,et al.  DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia , 2008, Clinical Cancer Research.

[16]  C. Harley,et al.  Telomerase and cancer therapeutics , 2008, Nature Reviews Cancer.

[17]  M. Lieber,et al.  Mechanistic flexibility as a conserved theme across 3 billion years of nonhomologous DNA end-joining. , 2008, Genes & development.

[18]  G. Salles,et al.  Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. , 2008, Blood.

[19]  S. Gibson,et al.  Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. , 2008, British journal of haematology.

[20]  Katarzyna Sikora,et al.  Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation. , 2007, Molecular cell.

[21]  W. Plunkett,et al.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance , 2007, Current Oncology Reports.

[22]  B. Jean-Claude,et al.  Chlorambucil Cytotoxicity in Malignant B Lymphocytes Is Synergistically Increased by 2-(Morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-Mediated Inhibition of DNA Double-Strand Break Repair via Inhibition of DNA-Dependent Protein Kinase , 2007, Journal of Pharmacology and Experimental Therapeutics.

[23]  M. Mattson,et al.  DNA damage responses in neural cells: Focus on the telomere , 2007, Neuroscience.

[24]  M. Boccadoro,et al.  Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients , 2007, Leukemia.

[25]  P. Carli,et al.  Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome , 2007, Leukemia.

[26]  J. Shay,et al.  Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. , 2007, Cancer research.

[27]  S. Pileri,et al.  Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase , 2006, Journal of Clinical Pathology.

[28]  M. Hallek,et al.  Fludarabine in chronic lymphocytic leukaemia , 2006, Expert opinion on pharmacotherapy.

[29]  C. Autexier,et al.  The structure and function of telomerase reverse transcriptase. , 2006, Annual review of biochemistry.

[30]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[31]  C. Autexier,et al.  Pharmacological Telomerase Inhibition Can Sensitize Drug-Resistant and Drug-Sensitive Cells to Chemotherapeutic Treatment , 2005, Molecular Pharmacology.

[32]  C. Harley,et al.  Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition , 2005, Oncogene.

[33]  S. Lees-Miller,et al.  Human Ku70/80 interacts directly with hTR, the RNA component of human telomerase , 2005, Nucleic acids research.

[34]  B. Salles,et al.  The Double Life of the Ku Protein: Facing the DNA Breaks and the Extracellular Environment , 2005, Cell cycle.

[35]  S. Lees-Miller,et al.  Biochemical characterization of the ataxia-telangiectasia mutated (ATM) protein from human cells. , 2004, DNA repair.

[36]  P. Gregersen,et al.  Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. , 2004, Blood.

[37]  S. Deaglio,et al.  CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. , 2003, Blood.

[38]  C. Harley,et al.  A novel telomerase template antagonist (GRN163) as a potential anticancer agent. , 2003, Cancer research.

[39]  E. Choi,et al.  Heterogeneous expression of Ku70 in human tissues is associated with morphological and functional alterations of the nucleus , 2002, The Journal of pathology.

[40]  A. Schnapp,et al.  Mechanism of Human Telomerase Inhibition by BIBR1532, a Synthetic, Non-nucleosidic Drug Candidate* , 2002, The Journal of Biological Chemistry.

[41]  H. Mizoguchi,et al.  Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. , 2002, Cancer letters.

[42]  E. Hendrickson,et al.  Ku86 is essential in human somatic cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Bachand,et al.  Human telomerase RNA-protein interactions. , 2001, Nucleic acids research.

[44]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.

[45]  L. Chieco‐Bianchi,et al.  Telomerase activity in chronic lymphoproliferative disorders of B‐cell lineage , 1999, British journal of haematology.

[46]  A. Pettitt,et al.  Purine analogues kill resting lymphocytes by p53‐dependent and ‐independent mechanisms , 1999, British journal of haematology.

[47]  C. Anderson,et al.  DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues , 1999, Oncogene.

[48]  C. Autexier,et al.  Tetrahymena telomerase ribonucleoprotein RNA-protein interactions. , 1999, Nucleic acids research.

[49]  W. Hilbe,et al.  Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. , 1998, Cancer research.

[50]  V. Callea,et al.  In vitro drug‐induced cytotoxicity predicts clinical response to fludarabine in B‐cell chronic lymphocytic leukaemia , 1998, British journal of haematology.

[51]  L. Panasci,et al.  Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. , 1998, Cancer research.

[52]  F. Caligaris‐cappio.  B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. , 1996, Blood.

[53]  B. Leber,et al.  Telomerase activity in normal leukocytes and in hematologic malignancies. , 1995, Blood.